Apocynin prevents isoproterenol-induced cardiac hypertrophy in rat

Area of Science:

• Cardiovascular Research
• Oxidative Stress Biology
• Pharmacology

Background:

• Oxidative stress contributes to cardiovascular diseases like cardiac hypertrophy, but antioxidant therapies have shown limited success.
• NADPH oxidase is a key source of reactive oxygen species in the heart.

Purpose of the Study:

• To investigate the therapeutic potential of apocynin (Apo), a NADPH oxidase inhibitor, in preventing cardiac hypertrophy.
• To evaluate Apo's effects on reactive oxygen species production and cardiac remodeling under beta-adrenergic stimulation.

Main Methods:

• Male Wistar rats were treated with isoproterenol (Iso) to induce cardiac hypertrophy, with or without apocynin (Apo).
• Cardiac hypertrophy was assessed using heart weight to body weight (HW/BW) and heart weight to tibia length (HW/TL) ratios, echocardiography, and histopathology.
• Gene expression of hypertrophy markers (ANP, BNP, β-MHC, ACTA-1) and NADPH oxidase subunits (cybb, p22-phox) was analyzed.
• Reduced glutathione levels and signaling kinase activation (PKA, Erk, Akt) were measured.

Main Results:

• Apocynin (Apo) administration blocked isoproterenol (Iso)-induced increases in HW/BW and HW/TL ratios, and prevented cardiac structural changes.
• Iso treatment elevated transcript levels of NADPH oxidase subunits (cybb, p22-phox) and hypertrophy markers, which were reduced by Apo.
• Iso decreased reduced glutathione levels, an effect reversed by Apo treatment.
• Apocynin inhibited the activation of key signaling kinases (PKA, Erk, Akt) induced by Iso.

Conclusions:

• Apocynin effectively ameliorates adrenergic stress-induced cardiac hypertrophy in rats.
• The findings support the therapeutic value of targeting NADPH oxidase with apocynin for cardiovascular protection.